期刊文献+

拉米夫定耐药株感染者HBV基因型和逆转录酶区变异分析 被引量:2

The hepatitis B viral genotype and mutations of reverse transcriptase domain analysis in patients with lamivu-dine-resistant mutant infection
下载PDF
导出
摘要 目的了解拉米夫定耐药株感染者HBV基因型特征并分析耐药株HBV逆转录酶(RT)区变异位点和变异类型。方法应用PCR扩增和直接测序HBV逆转录酶区并与Genebank中90株不同基因型野毒株序列进行比较,确定54例耐药株感染者HBV基因型和HBVRT核苷酸的变异特点。结果在54例拉米夫定耐药株感染者中,HBVB基因型占27.78%,C型占70.37%,B/C混合型占1.85%;51例患者出现RT保守区氨基酸变异(包括550和526位氨基酸变异);18例患者出现除主型区外HBVRT非主型区伴随变异;3例患者未检测到与拉米夫定相关性变异。结论拉米夫定耐药株感染者HBV基因型主要为B型和C型;拉米夫定耐药株的氨基酸变异不仅见于RT区的526和550两个位点,其他位点以及RT非保守区也可发生变异。 Objective To investigate the hepatitis B viral genotype and mutations of reverse transcriptase domain in patients with lamivudine-resistant mutant infection. Methods Hepatitis B virus genotypes in 54 patiens with chronic hepatitis B were assayed and HBV reverse transcriptase sequences were analyzed by PCR and gene sequencing. Result Out of the 54 patients,15(27.78%) were with HBV genotype B,38(70.37%) with genotype C,and 1(1.85%) with mixed B and C infection;51 patients had amino acid variation at HBV RT domains (including sites of 550 and 526),18 had additional amino acid variation at HBV non-conservative domains and 3 didn't have their amino acid variation detected. Conclusion HBV genotype B and C are the major HBV genotypes in this series of patients;Lamivudine-resistant HBV strains may accompany amino acid variation not only in the sites of 550 and 526 of HBV RT conservative domains,but also in the non-conserved domains outside YMDD motif.
出处 《实用肝脏病杂志》 CAS 2009年第5期345-346,365,共3页 Journal of Practical Hepatology
关键词 慢性乙型肝炎 HBV基因型 拉米夫定 YMDD基序变异 Hepatitis B Genotypes Lamivudine YMDD motif
  • 相关文献

参考文献11

  • 1KALYANDA S,XIONG XF,YANG HL,et al. Molecular modeling and bicohemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC)[J]. Virology, 2001,75 (10) :4771-4779.
  • 2SIMON A,DAVE B,CHONG GT,et al. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the light cycler [J]. Clin Micr biol,2001,39(4): 1456-1459.
  • 3WRIGHT TL. Chronic hepatitis B infection [J]. Am J Gastroententerol, 2006, 101 Suppl 1 : S 1-6.
  • 4WATANABE K,TAKAHASHI T,TAKAHASHI S.Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations[J]. J Gastroenterol Hepatol, 2005,20 : 441- 449.
  • 5YUEN MF,TANAKA Y,MIZOKAMI M,et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma:a case control study[J]. Carcinogenesis, 2004,25:1593-1598.
  • 6LOK A,MCMAHON B. Chronic hepatitis B[J]. Hepatology, 2001,34 : 1225-1241.
  • 7HAGH EC,VILLENEUVE JP. Lamivudie treatment in patients with chornic hepatitis B and cirrhosis[J]. Expert Opin Pharmacother, 2006,7 ( 13 ) : 1835-1843.
  • 8陈立,张欣欣.核苷(酸)类似物耐药变异对乙型肝炎病毒生物学特性的影响[J].中国实用内科杂志,2007,27(15):1230-1232. 被引量:7
  • 9ZOLLNER B,STENRECK M,WURSTHONR K,et al. Pervalence,incidence, and cilnicale relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy [J]. Clin Micorbiol, 2005,43 (5) : 2503-2505.
  • 10TORRES J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus[J]. Clin Virol,2002,25(2):97- 106.

二级参考文献1

共引文献6

同被引文献21

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部